This trial is evaluating whether KTE-C19 will improve 2 primary outcomes and 17 secondary outcomes in patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL). Measurement will happen over the course of Baseline up to 21 days.
This trial requires 37 total participants across 1 different treatment group
This trial involves a single treatment. KTE-C19 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Until now, no reliable cure has been found for large B-cell lymphoma. However, the number of patients in the various groups and their overall survival rate are better than the ones reported for non-Hodgkin's lymphoma. Also, survival rates from 1.45 years ago are higher than today." - Anonymous Online Contributor
"Patients with primary non-Hodgkin's lymphoma and a history of previous Epstein-Barr virus serologic reactivity of lymphocytes have an increased risk of development of large cell lymphoma. Further studies are warranted to determine the relation between Epstein-Barr virus and large cell lymphoma." - Anonymous Online Contributor
"Lymphoma is often treated with conventional chemotherapy followed by curative surgery, rituximab/RFTX in high-grade or rituximab in low-grade follicular, small lymphocytic, or [mantle cell lymphoma](https://www.withpower.com/clinical-trials/mantle-cell-lymphoma)s, alkylating chemotherapy for non-Hodgkin's lymphoma (NHL), R-CHOP for chemoresistant diffuse large B cell lymphoma (DLBCL), rituximab for refractory follicular NHL, and allogeneic stem cell transplantation for severe disease." - Anonymous Online Contributor
"The incidence of lymphoma, large-b-cell, diffuse is relatively high. Thus, further studies are indicated to determine the impact of this cancer in the U.S. population." - Anonymous Online Contributor
"Patients diagnosed with large B-cell lymphoma, diffuse are a heterogeneous group of patients with similar clinical presentations. The most relevant initial signs depend on the initial presentation of a large B-cell lymphoma, diffuse patient." - Anonymous Online Contributor
"Lymphoma, large-cell, large-b-cell, diffuse is a cancer that involves one or more lymph nodes and usually involves the peripheral or central areas of the body, such as the arms or legs. It is most common in individuals 45 years of age and older. It may be found in children, but is much less frequent in that age group. People usually present with symptoms of a mass or swelling." - Anonymous Online Contributor
"This article has identified key factors for clinical trial enrollment. Patients must have a life expectancy of at least another year and a substantial probability of relapse, but there is a broad range of acceptable candidates." - Anonymous Online Contributor
"Patients with lymphoma, large B-cell diffuse have a slightly higher risk of lymphoma, large B-cell non-deletion but this trend is no longer statistically significant after a adjustment for clinical information." - Anonymous Online Contributor
"Findings from a recent study indicate that K19 is used in combination with cytotoxic chemotherapy in more than 90% of patients with mantle cell lymphoma to improve overall survival. Therefore, K19 is currently used in combination with conventional chemotherapy in mantle cell lymphoma." - Anonymous Online Contributor
"There has been significant advancement in treating HL, Large B-Cell NHD and it is reasonable that this advancement will continue the future. The treatment of HL and other B-cell lymphomas should be customized for each individual depending on their staging and characteristics that are known to affect outcome, which includes age: age is one that many doctors and families wish to consideration." - Anonymous Online Contributor
"Although the majority of cases received standard chemotherapy treatment, a substantial subset of patients was not adequately treated. Some patients were inappropriately treated, with a poor prognosis. The authors emphasize that complete blood counts, with a focus on white blood cells and red blood cells, for early diagnosis and treatment are essential in all patients treated by kte-ck19." - Anonymous Online Contributor
"Results from a recent paper reveals that kte-c19 is safe and effective for people with lymphoproliferative disorders and rheumatoid arthritis. It is also effective in people with other autoimmune diseases although there is a less pronounced effect in these patients." - Anonymous Online Contributor